GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Net Income Including Noncontrolling Interests

Neurizon Therapeutics (FRA:ECQ0) Net Income Including Noncontrolling Interests : €-4.73 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Neurizon Therapeutics's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was €-0.24 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.73 Mil.

Neurizon Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Neurizon Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Net Income Including Noncontrolling Interests Chart

Neurizon Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.84 -0.85 -1.14 -3.85 -4.73

Neurizon Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.01 -3.83 -0.24 -4.49

Neurizon Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-4.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurizon Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ASX:RCE ASX:AGN ASX:PIQ ASX:ACW ASX:PAR ASX:EZZ ASX:TYP ASX:RAD ASX:ADO ASX:SPL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
ECQ0:Germany NUZ:Australia
Address
96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205
Website
https://www.neurizon.com
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines